Protest and strikes of the CGT union 2021

iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors

Retrieved on: 
Thursday, January 26, 2023

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding.

Key Points: 
  • LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding.
  • “Current vector production methods continue to struggle to meet clinical and commercial demand,” remarked Dr. Rodney Rietze, iVexSol co-founder and CEO.
  • “Our cost-effective and highly scalable Intelligent Vector Solutions are designed to break the vector supply bottleneck and provide greater access to patients seeking life-saving treatments.
  • These advances enable shorter clinical development timelines, reduced costs, and ultimately, increased global access for patients waiting to receive these transformative medicines.

Seven Specialty Pharmacy Trends to Watch in 2023

Retrieved on: 
Tuesday, January 10, 2023

AscellaHealth , a global healthcare and specialty pharmacy (SP) solutions company, has released its list of SP industry trends to watch in 2023, including numerous positive developments that impact all stakeholders in the ecosystem and care continuum spanning patients, payers, life sciences manufacturers and providers.

Key Points: 
  • AscellaHealth , a global healthcare and specialty pharmacy (SP) solutions company, has released its list of SP industry trends to watch in 2023, including numerous positive developments that impact all stakeholders in the ecosystem and care continuum spanning patients, payers, life sciences manufacturers and providers.
  • “In 2023, these market developments require targeted programs and complete end-to-end solutions that ensure medication access and affordability, cost management and opportunities for improving patient outcomes.
  • The specialty pharmaceuticals market is expected to grow at a significant CAGR of 35.4% by 2027 while gene/cell therapy market will reach $21.33 billion in 2026 at a CAGR of 25.6%.
  • This enables payers to gain better control over SP costs, have greater transparency into their benefit claims and strengthen their negotiating power.

Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

Retrieved on: 
Thursday, November 10, 2022

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for third quarter ending September 30, 2022.

Key Points: 
  • Orgenesis to Host Conference Call on Friday, November 11, 2022 at 8:00 AM Eastern Time
    GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc .
  • Vered Caplan, CEO of Orgenesis, said, We have made significant progress in advancing the rollout of our POCare platform.
  • This transaction was highly strategic for the Company and we believe that it provides further validation of our business model.
  • While we are pleased to have achieved revenue of approximately $8.0 million for the third quarter, we were limited by capital constraints.

Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

Retrieved on: 
Thursday, November 10, 2022

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 849908.

Key Points: 
  • The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 849908.
  • A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2585/47112 or on the Companys Investor Events section of the website here .
  • A webcast replay will be available on the Companys Investor Events section of the website ( https://ir.orgenesis.com/events#/ ) through Saturday, November 11, 2023.
  • We undertake no obligation to revise or update any forward-looking statement for any reason.

Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services

Retrieved on: 
Monday, November 7, 2022

The initial investment of $30 million will consist of $20 million in cash and conversion of the convertible loan Metalmark previously provided to Morgenesis in August 2022.

Key Points: 
  • The initial investment of $30 million will consist of $20 million in cash and conversion of the convertible loan Metalmark previously provided to Morgenesis in August 2022.
  • We are excited to partner with Vered Caplan and the entire Morgenesis team, said Howard Hoffen, Chairman and CEO of Metalmark.
  • We have selected Metalmark Capital as a partner in the POCare services subsidiary for their history of investment and success in the pharmaceutical services sector.
  • William Blair & Company, LLC served as exclusive financial advisor to Metalmark and Davis Polk & Wardwell, LLP served as legal counsel to Metalmark.

Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

Retrieved on: 
Tuesday, August 16, 2022

GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022.

Key Points: 
  • Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time
    GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc .
  • (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022.
  • Vered Caplan, CEO of Orgenesis, said, We are progressing with our transition to the second phase of the planned rollout of our POCare platform.
  • This includes revenue generation from the validation, process development, and supply of advanced therapies that utilize our POCare platform and Orgenesis Mobile Processing Units and Labs (OMPULs).

Orgenesis Schedules Second Quarter 2022 Business Update Conference Call

Retrieved on: 
Monday, August 15, 2022

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 223911.

Key Points: 
  • The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 223911.
  • A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2585/46399 or on the Companys Investor Events section of the website here .
  • A webcast replay will be available on the Companys Investor Events section of the website ( https://ir.orgenesis.com/events#/ ) through Wednesday, August 16, 2023.
  • We undertake no obligation to revise or update any forward-looking statement for any reason.

The Age of Cell and Gene Therapies is Upon Us - What Does it Mean for Bioanalysis?

Retrieved on: 
Wednesday, June 8, 2022

TORONTO, June 8, 2022 /PRNewswire-PRWeb/ -- Cell and gene therapies (CGTs) are types of treatment that use cellular or genetic material with the goal of treating a disease or a disorder. Often it can be a combination of cell and gene therapies, which is the case for chimeric antigen receptor T (CAR T) cells. As of March 2022, there are 20 US Food and Drug Administration (FDA) approved cell and gene therapy (CGT) licensed products from the Office of Tissues and Advanced Therapies (OTAT) and according to clinicaltrials.gov over 2,000 active CGT clinical trials.

Key Points: 
  • TORONTO, June 8, 2022 /PRNewswire-PRWeb/ -- Cell and gene therapies (CGTs) are types of treatment that use cellular or genetic material with the goal of treating a disease or a disorder.
  • Often it can be a combination of cell and gene therapies, which is the case for chimeric antigen receptor T (CAR T) cells.
  • Join this webinar to explore what the advent of cell and gene therapies mean for bioanalysis.
  • For more information, or to register for this event, visit The Age of Cell and Gene Therapies is Upon Us!

Cell and Gene Therapy Global Market Report 2022 Featuring Gilead Sciences, Bristol-Myers Squibb, Novartis, Amgen, Merck, Organogenesis, Dendreon, Vericel, Bluebird Bio and Fibrocell Science - ResearchAndMarkets.com

Retrieved on: 
Friday, May 27, 2022

Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.

Key Points: 
  • Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.
  • The cell and gene therapy market consist of sales of cell and gene therapies by entities (organizations, sole traders and partnerships) that develop cell and gene therapies.
  • The main types of products in cell and gene therapy are cell therapy and gene therapy.
  • Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market.

Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

Retrieved on: 
Tuesday, May 24, 2022

Specifically, we are conducting work related to validation, process development, and supply for clinical trials of advanced therapies utilizing our POCare platform and OMPULs.

Key Points: 
  • Specifically, we are conducting work related to validation, process development, and supply for clinical trials of advanced therapies utilizing our POCare platform and OMPULs.
  • As these activities ramp up, we expect to benefit from recurring revenue streams, based on long term contracts for the next two to three years.
  • We are currently working to expand our capacity to supply products for over 10 distinct clinical programs.
  • We believe our approach is highly scalable and provides us diversification across multiple revenue generating contracts.